The therapeutic armamentarium for management of inflammatory bowel diseases has
expanded dramatically in the last 5 years, with the introduction of several medications with …

Ulcerative colitis (UC) is a chronic and progressive inflammatory disorder that affects the
colon. The advent of advanced therapies such as biologic agents and small molecules has …

Simple Summary Patients with inflammatory bowel disease (IBD) are at an increased risk of
develo** colorectal cancer (CRC), mainly because of chronic intestinal inflammation …

Background Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and
ulcerative colitis (UC), continues to challenge treatment paradigms. Advancements in …

Advances in science have led to the development of multiple biologics and small molecules
for the treatment of inflammatory bowel diseases (IBDs). This growth in advanced medical …

Background Risankizumab, a humanized IgG1 monoclonal antibody that selectively inhibits
IL-23, is currently approved for the treatment of moderate-to-severe plaque psoriasis and …

IL23 is a recognized cytokine involved in the path-ogenesis of inflammatory bowel disease
(IBD). 1 The first IL23-targeting agent that became available for clinical use in IBD was …

Pediatric Crohn's disease commonly presents with moderate-to-severe intestinal
inflammation with a greater risk of complications if remission is not achieved. Anti-tumor …

Crohn's disease (CD) is a chronic, complex inflammatory disorder of the gastrointestinal tract
that presents significant therapeutic challenges. Despite the availability of a wide range of …

Risankizumab is a humanized monoclonal antibody that inhibits the p19 subunit of IL-23
cytokine. Recently it has been approved for the treatment of patients with moderate-to …